"Americans are fat and getting fatter," wrote Reason's Ron Bailey in a March 2023 piece about obesity and the hope such ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Oct 2024 - Stocks declined on Thursday as rising tensions in the Middle East left investors uneasy ahead of September's payrolls report.

OpenAI nearly doubles valuation to $157 billion in latest funding round, Tesla deliveries rose but analysts wanted more, and ...

In this article, we will discuss: 12 Best Growth Stocks To Buy According To Hedge Funds.

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Weight loss injections are medications that help the user lose weight. These drugs have been increasing in popularity over ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.